Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback